Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
A phase II prospective, non-randomized study. The study aim is to evaluate the feasibility
and activity of high-dose therapy with stem cell in elderly patients with aggressive lymphoma
relapsed FIT or resistant to first line therapy.